Remibrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), primarily developed for the treatment of autoimmune and inflammatory conditions. It is being investigated for its efficacy in chronic spontaneous urticaria (CSU), where it helps reduce hives and itching by blocking BTK-dependent signaling pathways involved in mast cell and basophil activation. Due to its high selectivity, remibrutinib offers a favorable safety profile with reduced off-target effects, making it suitable for long-term therapy. Its oral bioavailability allows for convenient dosing, and clinical trials have shown rapid symptom control in patients unresponsive to antihistamines. Research is also exploring its potential in other B-cell and mast cell-driven diseases, including certain dermatological and allergic disorders.